The Medical Developments share price is now down 49% over the past year

Will Penthrox manufacturer Medical Developments International Ltd (ASX:MVP) get FDA approval in the US?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Last month Medical Developments International Ltd (ASX: MVP) reported its half-year results for the period ending December 31 2018. Below is a summary of the results with comparisons to the prior corresponding half year.

  • Net profit after tax of $132,000, up 3.9%
  • Earnings before interest and tax $136,000, down 4.9%
  • Revenue of $9.52m, up 22%
  • Earnings per share of 0.21c
  • Fully franked interim dividend of 2 cents per share
  • Cash on hand of $32.3m
  • Penthrox (green whistle) sales up 37%
  • Penthrox sales in Europe and UK up 375%
  • Other medical device sales up 6%

So why has the Medical Developments share price collapsed in half over the past year?

Despite some strong looking headline numbers MVP shares have fallen as the company has struggled so far to get its key Penthrox (emergency pain relief product used by ambulance crews, field medics, etc) product approved in the lucrative U.S. healthcare market.

Today Medical Developments' management team told investors it expects to meet with the U.S. healthcare regulator the FDA in the final quarter of fiscal 2019 to discuss the FDA's "Clinical Hold" status issued in August 2018 on the Penthrox product.

MVP's management will attend the meeting armed with plenty of new data (including safety and clinical trial data) presumably in order to try and agree some sort of roadmap to get the product approved in the US.

Outside the U.S. problems, sales continue to perform well and the company has big plans to expand further into Europe, Asia, and China. In total it expects to launch the product in another 31 countries over the next 12 months.

The company has a market value around $261 million based on a $3.99 share price, which means a lot of growth is still baked into the valuation despite the precipitous valuation falls recently.

Others in the up-and-coming healthcare space to consider include Nanosonics Ltd (ASX: NAN) or even SomnoMed Limited (ASX: SOM).

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned. You can find Tom on Twitter @tommyr345 The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

The worst 3 ASX 200 stocks to buy and hold in October unmasked

You would have done well to avoid these three ASX 200 stocks in October.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why AFT, Amcor, Corporate Travel, and Macquarie shares are falling today

These shares are ending the week in the red. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why AGL, Imugene, Star, and Woolworths shares are dropping today

These shares are dropping on Thursday. Let's see why investors are selling them.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Fallers

Why Corporate Travel Management, JB Hi-Fi, Mineral Resources, and Syrah shares are rising

These shares are having a strong session. Why are investors buying their shares?

Read more »

A guys points his fingers down.
Share Fallers

Why Brainchip, Cettire, Star, and Woolworths shares are being sold off today

These shares are having a difficult time on hump day. But why?

Read more »

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why Black Cat, BlueScope, Cettire, and Coronado shares are falling today

These shares are missing out on the good times on Tuesday. But why?

Read more »

a business man in a suit holds his hand over his eyes as he bows his head in a defeated post suggesting regret and remorse.
Share Fallers

Why Adriatic Metals, Metcash, Paladin Energy, and Westgold shares are tumbling today

These shares are starting the week in the red. But why?

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Down 36% in 3 weeks, why is the Mineral Resources share price getting hammered again on Friday?

ASX investors are bidding down Mineral Resources shares again on Friday.

Read more »